RD

Rudi Dobber

Director Director DIN 01382863
DIN 01382863 First appointment Feb 2007 Primary industry General Business
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 0 active board seats
Past companies 1 historical roles
Total affiliations 1 Since Feb 2007
Shareholding value Locked Premium profile

About Rudi Dobber

Data last updated:

Rudi Dobber has 19 years in corporate governance. Formerly with 1 company, such as Astrazeneca Pharma India Limited. Engaged in General Business. Contributes to corporate operations.

DIN 01382863
Primary Designation Director
First Appointment 23 Feb 2007
Oldest Company Age Not Provided

Current companies

No current companies available.

Previous companies

CompanyDesignationAppointmentFoundedStatus
Astrazeneca Pharma India Limited L24231KA1979PLC003563
Director Appointed In Casual Vacancy23 Feb 20071979Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Astrazeneca Pharma India Limited
Premium access

Shareholding and investment profile for Rudi Dobber

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Rudi Dobber

Rudi Dobber has 19 years in corporate governance. Formerly with 1 company, such as Astrazeneca Pharma India Limited. Engaged in General Business. Contributes to corporate operations.

Rudi Dobber is associated with 0 companies as a director.

Rudi Dobber has expertise in General Business.

Rudi Dobber has 19 years in corporate governance.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available